Rockwell Medical (NasdaqCM:RMTI) Q4 2025 Earnings call March 26, 2026 08:00 AM ET Company ParticipantsAnthony Vendetti - Executive Managing Director of ResearchHeather Hunter - COOJesse Neri - SVP and CFOMark Strobeck - President and CEOConference Call ParticipantsRam Selvaraju - Senior Healthcare Equity Research AnalystOperatorGood morning, and welcome to Rockwell Medical's Fourth Quarter and Full Year 2025 Results Conference Call and Webcast. Please note this event is being recorded. At this time, I would ...

Rockwell Medical (NasdaqCM:RMTI) Q4 2025 Earnings call March 26, 2026 08:00 AM ET Company ParticipantsAnthony Vendetti - Executive Managing Director of ResearchHeather Hunter - COOJesse Neri - SVP and CFOMark Strobeck - President and CEOConference Call ParticipantsRam Selvaraju - Senior Healthcare Equity Research AnalystOperatorGood morning, and welcome to Rockwell Medical's fourth quarter and full year 2025 results conference call and webcast. Please note this event is being recorded. At this time, I would ...

Rockwell Medical (NasdaqCM:RMTI) Q4 2025 Earnings call March 26, 2026 08:00 AM ET Speaker4Good morning, and welcome to Rockwell Medical's fourth quarter and full year 2025 results conference call and webcast. Please note this event is being recorded. At this time, I would like to turn the conference call over to Heather Hunter, Chief Operating Officer at Rockwell Medical. Heather, please go ahead.Speaker1Good morning, and thank you for joining us for this update on Rockwell Medical. Joining me on today's co ...

Rockwell Medical (RMTI) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.04. This compares to a loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -125.00%. A quarter ago, it was expected that this maker of products used in the treatment of kidney disease and anemia would post a loss of $0.04 per share when it actually produced a loss of $0.05, delivering a surprise of -25% ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-23661 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

Investor Presentation March 26, 2026 | • hemodialysis products for dialysis providers worldwide | Healthcare company that develops, manufactures, commercializes, and distributes a portfolio of | | | | --- | --- | --- | --- | | • Business Overview | | | | | Leading supplier of liquid bicarbonate hemodialysis concentrates in the U.S. | | | | | • | One of the largest suppliers of acid and dry bicarbonate concentrates in the U.S. | | | | • | Infrastructure and logistics capabilities to serve 12,000+ purchasing ...

Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results Share WIXOM, Mich.--(BUSINESS WIRE)--Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and twelve mon ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Rockwell Medical has been recognized as a Great Place to Work for the fourth consecutive year, highlighting the importance of its employees in driving the company's success [1][1][1] Company Overview - Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company focused on developing, manufacturing, and distributing hemodialysis products for dialysis providers globally [1][1] - The company aims to provide high-quality products and exceptional customer service to dialysis clinics and patients [1][1] Employee Recognition - The Great Place to Work certification is based on employee feedback regarding their workplace experience, emphasizing a high-trust environment [1][1] - Rockwell Medical's Vice President of Human Resources stated that the recognition motivates the company to foster a supportive and empowering workplace culture [1][1] Commitment to Innovation - The company is dedicated to enhancing its products, processes, and workforce to drive long-term innovation and value [1][1] - Rockwell Medical is focused on delivering reliable and high-quality services to the dialysis community, which is crucial for patients with end-stage kidney disease [1][1]

Core Viewpoint - Rockwell Medical (RMTI) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [1][2]. - A strong correlation exists between changes in earnings estimates and near-term stock price movements, influenced by institutional investors who adjust their valuations based on these estimates [4][6]. Company Performance and Outlook - The upgrade indicates a positive outlook for Rockwell Medical's earnings, suggesting potential buying pressure and an increase in stock price [3][5]. - For the fiscal year ending December 2025, Rockwell Medical is expected to earn -$0.09 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 66.7% over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 places Rockwell Medical in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].